ZYBERNO
Stock Report
Updated Aug 26, 2026

LianBio (LIANY)

Healthcare • Over The Counter

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
LianBio (LIANY) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-58.7%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.03x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-93.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LianBio (LIANY) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (1)

Market Cap:$3.40M

Valuation Multiples (2)

P/B Ratio:0.02x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$98.22M

Price Action & Momentum (2)

B. Profitability Assessment

Return Metrics (5)

ROA:-46.0%
Reinvestment Rate:-0.9%
Fundamental Growth Rate (g):0.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$702.38
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:10.06x
Quick Ratio:10.06x
Cash Ratio:4.04x

Leverage Analysis (3)

Debt To Equity Ttm:0.03x
Debt-to-Equity Ratio:0.03x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-46.31x
Times Interest Earned:-46.31

Capital Structure (4)

Working Capital:232,178,000.00
Cash And Cash Equivalents:103,457,000.00
Long Term Debt:$213.00K
Net Debt:-$101.62M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

Gross profit TTM: $9.95M
Linear Growth: 100.0%
📊 Click to view full LIANY Gross Profit analysis & methodology →
-$106.56M

Bottom Line Performance (3)

-$137.60M
Income Before Tax:-$110.62M
Ebitda Ttm:-105,553,000.00

Operating Expenses (5)

Operating Expenses:26,301,000.00
R And D Expense:9,018,000.00
Sga Expense:17,283,000.00
Income Tax Expense:$586.00K
Interest Expense:2,707,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$262.90M
Current Assets:$257.81M
Ppe Net:2,364,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:26,790,000.00
Current Liabilities:25,627,000.00
Long Term Debt:$213.00K
Short Term Debt:$1.62M

Equity & Capital (3)

Equity:$202.34M
Retained Earnings:-$540.23M
Common Stock:2,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:6,229,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:13,310,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$15.06M-$101.03M

Investment Activities (2)

Investing Cash Flow:$78.04M
Capital Expenditures Ttm:-1,146,000.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,224,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.98
-$0.98
Earnings Per Share Ttm:-$1.03

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.93

Book Value & Capital (2)

Book Value Per Share:$1.89
Cash Per Share:0.97

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:105.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.9%
Fundamental Growth Rate (g):0.8%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):100.0%
Book Value Growth Rate (Linear):-26.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:LIANY
Company Name:LianBio
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:107.17M
Shares Outstanding Basic:107.17M
Shares Outstanding Diluted:107.17M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 12:08:02 UTC
Data Timestamp:2026-03-30T12:42:34.072188
Scroll to Top